Silo Pharma, Inc.

Silo Pharma reported a net loss of $0.83 million for the second quarter of 2026, an improvement from $1.20 million in the same period last year, with diluted EPS improving to $(0.76). However, the net loss for the first half of 2026 increased to $2.48 million. The company also announced the formation of Qwikagentsai Inc. to diversify into AI technology and completed a 1-for-15 reverse stock split in June 2026. Cash and cash equivalents decreased to $3.28 million, and license fee revenue was negligible.

Silo Pharma announced that the European Patent Office (EPO) granted a patent for its lead candidate SPC-15, an intranasal treatment for post-traumatic stress disorder (PTSD) and stress-induced affective disorders. This patent, EP3952852, covers methods of preventing stress-induced fear and depressive-like behavior by administering serotonin 4 receptor agonists before stress exposure. The company holds an exclusive license for this European patent from Columbia University, further strengthening its global intellectual property for this novel preventative approach.

Silo Pharma announced that its wholly owned subsidiary, QwikAgents, has partnered with Caylent, an Amazon Web Services (AWS) Premier Tier Services Partner, to develop a new AWS-native QwikAgents platform. This collaboration is designed to enhance the platform's scalability, performance, and security, accelerating its commercialization and future product innovation. The engagement is also structured to receive funding support from AWS and Caylent, positioning QwikAgents for significant enterprise growth.

Silo Pharma provided an update on the commercialization progress of its AI subsidiary, QwikAgents, and the advancement of its lead PTSD therapeutic program, SPC-15. The company expects to commercially launch its enhanced AI agent platform within the next 60-90 days, aiming to generate initial revenue. Concurrently, Silo is strengthening the intellectual property for SPC-15 and completing final regulatory activities for an FDA Type C meeting request, followed by an Investigational New Drug (IND) submission. The company states it is well-capitalized to pursue these opportunities after a recent private placement.

Silo Pharma announced that its subsidiary, QwikAgents, has been accepted into Advanced Micro Devices' (AMD) AI Developer Program. This participation grants QwikAgents access to AMD Developer Cloud credits, advanced AI development tools, and training resources, which are expected to accelerate the development, testing, and deployment of its AI agent platform. QwikAgents aims to make powerful, persistent AI agents accessible to a wide range of users, from individuals to enterprises, with affordable and scalable solutions.

Silo Pharma, Inc. announced a private placement that closed on July 10, 2026, generating approximately $4 million in gross proceeds. The placement involved the issuance of 619,965 shares of common stock (or pre-funded warrants) and associated Series A-3 and Series A-4 warrants. The company could receive an additional $7.7 million if all warrants are fully exercised for cash. Net proceeds, estimated at $3.5 million after deducting fees and expenses, will be allocated to working capital and general corporate purposes.

Silo Pharma, Inc. announced definitive agreements for a private placement expected to generate approximately $4 million in gross proceeds. The offering includes common stock and warrants, with potential for an additional $7.7 million if the warrants are fully exercised. The company intends to use the net proceeds for working capital and general corporate purposes, supporting its developmental-stage biopharmaceutical programs.

Silo Pharma announced that its wholly owned subsidiary, QwikAgents, has joined the NVIDIA Developer Program. This move is expected to enhance and advance QwikAgents' AI agent integration platform, which is designed to automate complex workflows using autonomous AI agents. Joining the program provides QwikAgents with access to NVIDIA's AI software ecosystem, development frameworks, and optimization resources, aiming to accelerate platform innovation for enterprise customers.

Silo Pharma announced it has engaged Resyca to conduct a robustness study evaluating the microchip-based nasal spray system for SPC-15, its lead intranasal prophylactic treatment for post-traumatic stress disorder (PTSD). This study is designed to assess device performance consistency and formulation stability over 30 days. The data from this study is expected to support a planned FDA Type C meeting request to obtain regulatory guidance for its IND strategy and Phase 1 clinical trial design, following a previous alignment with the FDA on a streamlined 505(b)(2) regulatory pathway for SPC-15.

Silo Pharma, a developmental-stage biopharmaceutical company, announced positive stability data for its investigational soft-mist intranasal prophylactic, SPC-15. The data confirmed the physical, chemical, and microbiological integrity of SPC-15's formulation over nine months of real-time testing and six months under accelerated conditions. This milestone supports the continued advancement of the company's FDA Investigational New Drug (IND)-enabling development program and validates adherence to cGMP standards, moving SPC-15 closer to a Phase 1 clinical study for stress-induced psychiatric conditions like PTSD and anxiety.